key: cord-0964339-hrj1vmr7
authors: Mantero, Vittorio; Baroncini, Damiano; Balgera, Roberto; Guaschino, Clara; Basilico, Paola; Annovazzi, Pietro; Zaffaroni, Mauro; Salmaggi, Andrea; Cordano, Christian
title: Mild COVID‐19 infection in a group of teriflunomide‐treated patients with multiple sclerosis
date: 2020-08-31
journal: J Neurol
DOI: 10.1007/s00415-020-10196-9
sha: ac916557de98e484a4db630723d98d2013db2303
doc_id: 964339
cord_uid: hrj1vmr7

nan

values are reported in table in Table 1 . Patients were mostly female (67%), with an average age of 45 (± 8.6) years and a disease duration of 15.8 (± 9.6) years. Median EDSS was 1.75 (range 1-4.5) , and the average time on treatment with teriflunomide was 2.1 (± 1.6) years. None of these patients presented relevant comorbidities.

None had lymphopenia, neutropenia or leukopenia. No patient required hospitalization, ICU care, or intubation. They all improved without receiving any specific treatment. One of the patients reported subjective diplopia, interpreted as a pseudo-relapse by the treating neurologist. Compared with the patients presented by Maghzi et al., the patients in our cohort were 8.6 years younger, average time on treatment with teriflunomide was about 0.5 years shorter, disease duration was 3 years longer and median EDSS was 0.75 point lower (2.5 with range 0-6 in Maghzi et al.). A weakness of our series is that infection was confirmed only in three patients.

Generally, patients with MS have an increased risk of infections [3] , with about twice the risk of hospitalization with respect to the general population [4] . Infections also have a role in triggering MS relapses or worsening pre-existing MS symptoms [5] , and they are more likely to happen in patients treated with disease-modifying therapies (DMTs), with a different risk depending on the mechanism of action of the drug [3] .

The risk and course of COVID-19 in patients with MS is still unclear. Sormani et al. reported on 232 patients with MS from 38 different Italian MS centers presenting COVID-19 infection, 223 of whom experienced mild symptoms, 4 experienced severe infection and 6 with critical conditions [6] . In a study by Safavi et al., patients who were on a B-cell depleting antibody were at a higher risk of developing COVID-19 infection and being hospitalized [7] . Few reports about other therapies have been reported in the literature [8] [9] [10] [11] [12] .

Teriflunomide is the active metabolite of leflunomide. Cai et al. reported a case of a patient with rheumatoid arthritis treated with leflunomide presenting a COVID-19 infection complicated by severe symptoms [13] .

Our small case series, although in a different population compared to the paper of Maghzi and coauthors [1] , seem to confirm that continuing therapy might be safe in teriflunomide-treated MS patients who develop COVID-19 infection. Withdrawal of teriflunomide does not seem to be necessary, especially if the lymphocyte count is higher than 500-800/mm 3 [14] .

Author contributions VM contributed to the conceptualization, gathering of data and drafting the manuscript; DB, RB, CG, PB, PA contributed to gathering of data and drafting the manuscript; MZ, AS, and CC contributed to drafting and revising the manuscript.

Conflicts of interest VM, DB, RB, CG, PB, PA and MZ served in advisory boards and/or received travel grant from Genzyme for participation at congress. AS and CC have no conflict of interest to disclose.

Ethical approval All procedures performed in this study were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent All patients provided consent to be anonymously included in this report. 

Bakshi R (2020) COVID-19 in teriflunomide-treated patients with multiple sclerosis

Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse

Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies

Infection-related health care utilization among people with and without multiple sclerosis

Infection as an environmental trigger of multiple sclerosis disease exacerbation

An Italian programme for COVID-19 infection in multiple sclerosis

B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran

Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod

COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role

Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: a mild uncomplicated infection despite intense immunosuppression

Covid-19 in a patient with multiple sclerosis treated with natalizumab: may the blockade of integrins have a protective role?

COVID-19 in dimethyl fumaratetreated patients with multiple sclerosis

A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab

Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic